The Application Value of Spectral CT in the Accurate Staging of Breast Cancer

Launched by YUNNAN CANCER HOSPITAL · May 16, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging technique called Spectral CT to help doctors better understand and diagnose breast cancer. The goal is to see if this advanced imaging can improve the accuracy of staging breast cancer, which means determining how advanced the disease is. By using this technology, researchers hope to provide better information for creating personalized treatment plans, ultimately aiming to improve the outcomes for patients with breast adenocarcinoma.

To be eligible for this trial, participants must be women aged 18 and older who have been suspected of having breast cancer and are willing to sign a consent form. However, individuals with certain health issues, such as severe heart or lung problems, or those who are allergic to iodine contrast (a substance used in some imaging tests), may not be able to participate. If you join the study, you will undergo a Spectral CT scan within a week before starting your treatment. This trial is not yet recruiting participants, so there may be some time before it begins.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • (a) Chest quark energy spectrum CT examination was performed within 1 week before treatment
• • (b) Age ≥ 18
• • (c) Suspected breast cancer patients
• • (d) Patients who signed informed consent
• Exclusion Criteria:
• • (a) Severe cardiac, pulmonary and renal insufficiency
• • (b) Allergic to iodine contrast media
• • (c) Unable to cooperate to complete CT examination
• • (d) Quark spectrum CT image is poor and cannot be used
• • (e) Male, pregnant and lactating female
• • (f) Combined with other tumor history
• • (g) Incomplete clinical and pathological data
• • (h) Pathologically confirmed non breast cancer